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Background: Consumption of antibiotics active against meticillin-resistant Staphylococcus
aureus (MRSA) has been described in numerous European studies. However, the underlying
predictors of consumption are still poorly understood.
Aim: To describe the consumption of anti-MRSA antibiotics (daptomycin, intravenous
glycopeptides, linezolid) in Switzerland over time and to identify underlying predictor
variables.
Methods: A retrospective observational multi-centre study was conducted in 21 Swiss
hospitals over a period of 11 years (2009e2019). Multiple linear regression models were
built to identify regional and hospital-specific predictor variables affecting the con-
sumption of anti-MRSA antibiotics.
Findings: Consumption of anti-MRSA antibiotics increased between 2009 and 2019 from
12.7 to 24.5 defined daily doses per 1000 bed-days (þ93%). In the first model presented,
which includes data of the whole study period, the following variables were associated
with higher anti-MRSA antibiotic consumption: number of MRSA cases (P < 0.01), year (P <
0.01), hospital type (tertiary care university hospitals vs others, P < 0.01), hospital
department (intensive care unit vs others, P < 0.01) and linguistic region (French vs
German and German vs Italian, P < 0.01). In a second model including data from a query
on hospital policies in place in 2019, the presence of an antibiotic stewardship group (P <
0.01) and prescription restrictions (P < 0.01) were associated with consumption of anti-
MRSA antibiotics.
Conclusion: Our study shows that both the presence of an antibiotic stewardship group
and the implementation of prescription restrictions, i.e. factors that can be controlled by
the hospital itself, were associated with a lower consumption of anti-MRSA antibiotics.
ª 2021 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).trasse 51, Bern, 3010, Switzerland. Tel.: þ41 31 632 98 80.
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Staphylococcus aureus was reported to be the second
most frequent micro-organism causing healthcare-associated
infections in Europe in 2017, causing sepsis, cardiac valve
infection, and joint, bone, wound, and soft tissue infections
[1]. Approximately 50% of the population are nasal carriers,
and they are widely disseminated [2]. Infections with
meticillin-resistant Staphylococcus aureus (MRSA), resistant
against all classical b-lactams, including combinations with b-
lactam inhibitors, represent a high risk, especially for seriously
ill and immunocompromised patients, and are therefore a
serious threat in hospitals worldwide. Despite decreasing MRSA
rates, deaths attributable to MRSA infections increased by a
factor of 1.38e6810 yearly deaths in Europe between 2007 and
2015 [3]. By causing 32.6 disability-adjusted life-years (DALYs)
per 100,000 individuals, MRSA ranked second of all DALYs
attributed to infections with antimicrobial-resistant bacteria in
the European Union (EU) and European Economic Area (EEA)
and ranked third in Switzerland (8.9 DALYs per 100,000 indi-
viduals [4]). For different linguistic regions in Switzerland, both
decreasing and slightly increasing MRSA rates were described
[5]. In 2019, the MRSA rate in Switzerland was 3.4%, with
slightly higher rates in southern and western Switzerland [6].
The emergence and spread of antimicrobial resistance are
favoured by antibiotic therapy through evolutionary pressure
[7e9]. Surveillance of antibiotic consumption is a crucial ele-
ment in ‘antibiotic stewardship’, and it has been shown that
optimizing the use of antibiotics may prevent the spread of
resistant bacteria [10].
Daptomycin, glycopeptides (vancomycin and teicoplanin),
linezolid, tigecycline, clindamycin, trimethoprimesulfameth
oxazole, fosfomycin, ceftobiprole, and ceftaroline are known
to be biologically active against MRSA [11,12]. However, intra-
venous glycopeptides and the reserve antibiotics daptomycin
and linezolid are the only effective options for the treatment of
MRSA bacteraemia. While intravenous glycopeptides are mainly
used against MRSA, daptomycin and linezolid may also be used
against vancomycin-resistant enterococci (VRE). Due to these
properties, we restrict our analysis to the glycopeptides dap-
tomycin and linezolid, referred to hereinafter as ‘anti-MRSA
antibiotics’.
Therapy with intravenous glycopeptides, which are known
for their relatively complex handling and toxicity, was the only
effective treatment against MRSA bacteraemia until the
introduction of linezolid in Switzerland in 2001. The intro-
duction of daptomycin followed in 2007. Daptomycin and
linezolid are comparable in their effectiveness, whereas the
incidence of thrombocytopenia is higher under linezolid
[13,14]. The potential effect of the introduction of daptomycin
on the consumption of glycopeptides and linezolid has not yet
been studied in Switzerland.
For different European countries, both increasing and
decreasing trends in consumption of anti-MRSA antibiotics have
been described for the period from 2010 to 2019 [15]. However,
to the best of our knowledge, the underlying predictors of
these long-term processes have only been studied to a limited
extent for glycopeptides.
The aims of this study were: (i) to describe the consumption
of anti-MRSA antibiotics in 21 Swiss hospitals from 2009 to 2019;
(ii) to identify underlying predicting parameters; and (iii) toPlease cite this article as: Renggli L et al., Consumption of anti-metic
associated with antibiotic stewardship measures, Journal of Hospital Infeinclude hospital policy-dependent predictors such as antibiotic
stewardship policies in a second model for 2019 only.
Methods
Design and study population
A retrospective observational multi-centre study was con-
ducted with data from 21 Swiss hospitals over a period of 11
years (2009e2019). To homogenize the dataset, analysis was
restricted to hospitals with more than 200 beds and data
availability for at least two years within the study period.
Data collection and processing
Antibiotic consumption and resistance data were obtained
from the Swiss Centre for Antibiotic Resistance (ANRESIS)
database. ANRESIS is a representative surveillance system that
continuously collects national data on antibiotic use and anti-
biotic resistance.
Yearly antibiotic consumption was described in defined daily
doses (DDD) per 1000 bed-days (BD) and reflects the amount of
antibiotics delivered from the hospital pharmacy to individual
departments [16].
MRSA was defined as Staphylococcus aureus non-susceptible
to at least one of the following antibiotics: meticillin, oxacillin,
flucloxacillin, or cefoxitin. VRE was defined as Enterococcus
faecalis or Enterococcus faecium non-susceptible to vanco-
mycin. Analyses were restricted to isolates from sterile sites,
surrogating invasive infections. Isolates obtained within 30
days after the first positive result for the same patient at the
same hospital were considered duplicate and were excluded.
Incidence is given by the number of invasive infections per 1000
bed-days. To obtain data on the 2019 hospital policies (i.e.
availability of guidelines for the treatment of MRSA infections
and restrictions for the use of daptomycin, glycopeptides and
linezolid), a short online questionnaire (Survs, https://survs.
com/) was sent to the infectious diseases specialists at par-
ticipating hospitals).
Statistical models
A multiple linear regression model was developed to iden-
tify predictor variables contributing to the consumption of
anti-MRSA antibiotics (DDD/1000 BD) from 2009 to 2019 (‘model
1’). The following predictor variables were included in the
initial model: MRSA incidence, VRE incidence, time (i.e. the
years), hospital type (university vs non-university hospital),
linguistic region (see details below) and intensive care unit
(ICU) vs non-ICU department. The initial model, which included
all predictor variables, was transformed logarithmically to
meet the assumptions for linear regression. The likelihood ratio
test (c2 statistics) was then used in a backwards elimination
process (P < 0.05 to retain) to select the set of independent
variables for the final model.
The German-speaking region was used as a reference in
comparisons of the three-level factor linguistic region. To
analyse differences between the French- and Italian-speaking
regions, the French-speaking region was additionally used as
a reference.illin-resistant Staphylococcus aureus antibiotics in Swiss hospitals is
ction, https://doi.org/10.1016/j.jhin.2021.08.019
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To improve the regression model, we included parameters
of the hospital policies into an additional model (‘model 2’).
Data for this model were restricted to the year 2019, as data on
hospital policies were available for this year only. Additional
dichotomous (‘yes’/‘no’) predictor variables included in this
model were the presence of an antibiotic stewardship group
(ABS group), meeting at least three times yearly, availability of
internal guidelines for treatment of MRSA infections, pre-
existing written restrictions in prescription of anti-MRSA anti-
biotics, recommendation of glycopeptides as the first choice
for empirical treatment of severe skin and soft-tissue infec-
tions, and routine testing of daptomycin resistance. The
questions which led to these variables where added to the
supplement (Survey Questions for Analysis 2019). The initial
model, which included all predictor variables, was transformed
logarithmically to meet the assumptions for linear regression.
The likelihood ratio test (c2 statistics) was then used in a
backwards elimination process (P< 0.05 to retain) to select the
set of independent variables for the final model.
All analyses and visualizations were performed with R soft-
ware (version 3.6.1, R Core Team, Vienna, Austria).Results
Temporal and regional patterns from 2009 to 2019
Total consumption of anti-MRSA antibiotics increased sig-
nificantly (P < 0.01) from 2009 to 2019 in Switzerland (Table I).
Consumption increased from 12.7 to 24.5 DDD/1000 BD (þ93%)
between 2009 and 2019, with the highest increase observed
between 2009 and 2013 (up to 22.2 DDD/1000 BD, þ75%).
Increases were observed for all anti-MRSA antibiotics (glyco-
peptides 11.2 to 16.9 (þ51%), daptomycin 1.4 to 7.9 (þ400%),Table I
Predictor variables of a model describing the consumption of anti-
MRSA antibiotics [log10(DDD/1000 BD)] in Switzerland from 2009 to
2019
Variable Estimatea 95% CI P-value
Year 0.04 (0.02, 0.05) <0.001
MRSA incidence 1.02 (0.89, 1.16) <0.001
ICU vs non-ICU 0.68 (0.51, 0.84) <0.001
University vs non-
university hospital
0.39 (0.25, 0.53) <0.001
French vs German 1.34 (1.21, 1.46) <0.001
Italian vs German 2.22 (0.88, 3.55) 0.001
MRSA and ICU interaction e0.78 (e1.01, e0.55) <0.001
University and French
interaction
e1.88 (e3.2, e0.55) 0.006
VRE incidence No associationb
R2/adjusted R2 0.731/0.725
F-statistic 130.2 <1 E-15
MRSA, meticillin-resistant Staphylococcus aureus; DDD, defined daily
doses; BD, bed-days; CI, confidence interval; ICU, intensive care unit;
VRE, vancomycin-resistant enterococci.
a Negative sign indicates a negative association.
b Variable does not improve the model (likelihood ratio c2-statistic, P
> 0.05).
Please cite this article as: Renggli L et al., Consumption of anti-metici
associated with antibiotic stewardship measures, Journal of Hospital Infeand linezolid 0.51 to 0.67 DDD/1000 BD (þ31%)) (Figure 1). The
percentage of daptomycin in the total consumption of anti-
MRSA antibiotics increased from 9% in 2009 to 28% in 2019,
whereas the proportion of glycopeptides decreased from 87%
to 70% and that of linezolid decreased slightly from 4% to 2.7%.
The results of model 1 showed that the number of MRSA
infections was positively associated with the consumption of
anti-MRSA antibiotics (P < 0.01, Table I). Consumption was
significantly higher in ICU departments than in non-ICU
departments (P < 0.01, Figure 2). Conversely, the effect of
MRSA incidence on consumption was lower in ICU departments
than in non-ICU departments (P < 0.01). Further predictor
variables were hospital type (P < 0.01) and linguistic region (P
< 0.01). VRE incidence was not associated with the con-
sumption of anti-MRSA antibiotics.
Consumption increased in all settings over time, with
the exception of French-speaking university hospitals
(Supplementary Table A1, Figure 2).
MRSA incidence decreased from 0.085 to 0.076 invasive
infections/1000 BD (e11%) between 2009 and 2019, with the
largest decrease between 2009 and 2013 (e22%). Remarkably,
the incidence of MRSA decreased in university hospitals in the
French-speaking region only (from 0.26 to 0.11 invasive infec-
tions/1000 BD, e58%), whereas increasing incidences were
observed in the other linguistic-hospital type combinations
(Supplementary Table A2, Figure 2). In ICU departments, MRSA
incidence was consistently higher than that in non-ICU
departments.Survey results for hospital policies in 2019
Nineteen out of 21 hospitals sent consumption data for
2019; 15 (79%) responded to the 2019 survey on hospital poli-
cies (11/13 from the German-, 4/4 from the French- and 0/2
from the Italian-speaking region). An infectious disease (ID)
specialist was on-site at each participating hospital, and anti-
biotic stewardship groups who met at least three times yearly
existed in eight (53%) of all hospitals. Guidelines concerning
antibiotics in general were available in 14 out of 15 (93%)






































Figure 1. Consumption of the anti-MRSA antibiotics (defined daily
doses (DDD) per 1000 bed-days) daptomycin (blue), glycopeptides
(intravenous vancomycin, teicoplanin, green) and linezolid (red)
in 21 Swiss hospitals between 2009 and 2019.











































































Figure 2. Median consumption of anti-MRSA antibiotics (defined daily doses (DDD) per 1000 bed-days (BD), upper panels) and MRSA
incidence (invasive infections per 1000 bed-days, lower panels) in university (solid line) and non-university (dashed line) hospitals of the
French-speaking (dark blue), German-speaking (light blue) and Italian-speaking (red) regions of Switzerland between 2009 and 2019 in
intensive care unit (ICU) (left panels) and non-ICU departments (right panels).
L. Renggli et al. / Journal of Hospital Infection xxx (xxxx) xxx4treatments were available in eight (53%) and four (27%) of all
hospitals, respectively. However, in four out of 11 (36%) hos-
pitals without MRSA/VRE guidelines, a consultation from an ID
specialist was automatically triggered after an MRSA or VRE
infection. In one out of 15 hospitals (7%) a limitation in treat-
ment days for intravenous glycopeptides was in place. More
hospitals had restrictions on prescriptions for daptomycin (87%)
than on those for linezolid (80%) or glycopeptides (27%). Com-
mon restrictions included an obligation to consult an ID spe-
cialist or the chief physician before prescription of anti-MRSA
antibiotics or automatic limitation of the treatment duration.
Other restrictions were the consultation of an ID specialist or
validation by a clinical pharmacist. The recommended daily
daptomycin doses for the treatment of skin and soft tissue
infections ranged between 4 and 10 mg/kg body weight (BW).
The recommended dosage in university hospitals was higher,
with a median of 8 mg/kg BW (interquartile range: 6e8 mg/kgPlease cite this article as: Renggli L et al., Consumption of anti-metic
associated with antibiotic stewardship measures, Journal of Hospital InfeBW), than that in non-university hospitals, with a median of 6
mg/kg BW (interquartile range: 4.5e6 mg/kg BW).
The hospital policy-dependent predictor variables, namely,
existing antibiotic stewardship group meeting at least three
times yearly and pre-defined restrictions on prescriptions,
were significantly (each P < 0.01) associated with lower con-
sumption of anti-MRSA antibiotics in 2019 (Table II, Figure 3).
Overall, the hospital policy-dependent factors explained 44%
of the variability explained by this model.
All hospitals had either an existing antibiotic stewardship
group, restrictions in prescription of anti-MRSA antibiotics, or
both. Restrictions could not be specified further due to multi-
collinearity of different restriction types.
Except for hospital type and ICU vs non-ICU department,
none of the predictors included in the initial model, including
linguistic regions and MRSA incidence, were significantly asso-
ciated with consumption of anti-MRSA antibiotics (Table II).illin-resistant Staphylococcus aureus antibiotics in Swiss hospitals is
ction, https://doi.org/10.1016/j.jhin.2021.08.019
Table II
Predictor variables, including hospital policies, of a model
describing the consumption of anti-MRSA antibiotics [log10(DDD/
1000 BD)] in Switzerland in 2019




1.15 (0.71, 1.6) <0.001
ICU vs non-ICU 1.01 (0.62, 1.4) <0.001
ABS group vs none e0.71 (e1.15, e0.26) 0.003
Restrictionsb vs
none
e0.97 (e1.59, e0.36) 0.003
French vs German No associationc
MRSA incidence No associationc





















F-statistic 16.93 <1 E-06
MRSA, meticillin-resistant Staphylococcus aureus; DDD, defined daily
doses; BD, bed-days; CI, confidence interval; ICU, intensive care unit;
VRE, vancomycin-resistant enterococci.
ABS group: antibiotic stewardship group present with regular meetings
(>3 times a year).
a Negative sign indicates a negative association.
b Restrictions on the prescription of anti-MRSA antibiotics.
c Variable does not improve the model (likelihood ratio c2-statistic, P
> 0.05).
d Glycopeptides as the first choice for empirical therapy of skin and
soft-tissue infections.
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Increasing consumption was observed for all anti-MRSA
antibiotics, despite decreasing MRSA incidences in Switzer-
land between 2009 and 2019. Remarkably, the use of dapto-
mycin, which was introduced in 2007, did not replace the use of
glycopeptides (Figure 1). This finding is in contrast to obser-
vations from France and Italy, where decreased glycopeptides
consumption was observed after the introduction of dapto-
mycin [17]. Similar trends as in Switzerland, i.e. no reduction in
glycopeptides consumption despite increasing consumption of
new MRSA antibiotics (daptomycin, linezolid) and stable MRSA
rates, were described in Spain between 2007 and 2012 [18].
However, according to stratified Swiss data, the overall
decrease in MRSA incidence was caused solely by French-
speaking university hospitals, in which consumption of anti-Please cite this article as: Renggli L et al., Consumption of anti-metici
associated with antibiotic stewardship measures, Journal of Hospital InfeMRSA antibiotics was stable. In other regions, both the MRSA
incidence and consumption of anti-MRSA antibiotics increased.
The finding that the consumption of anti-MRSA antibiotics in
the French- and Italian speaking parts of Switzerland was higher
than that in German-speaking regions may be explained by
socio-cultural factors and by higher MRSA rates in neighbouring
countries (2019: Italy 35.6%, France 11.6%, Germany 6.7%), as
patients and medical staff exchange across the national borders
[19e21]. Different MRSA rates, as well as different background
of treating physicians, both influence prescription of anti-MRSA
antibiotics which always is a balance between avoiding risks for
the patient and avoiding resistance development. Development
and advertisement of own national guidelines could help to
further reduce these differences. Similar consumption patterns
within Switzerland were described by Plüss-Suard et al. for
vancomycin between 2004 and 2008 [22].
The consumption of anti-MRSA antibiotics in university
hospitals was higher than that in non-university hospitals. In
addition to the higher MRSA rates observed in French university
hospitals only, the higher consumption in university hospitals is
probably caused by the more severe and complex cases
accommodated in higher-level-of-care hospitals, assuming that
critically ill patients are more likely to be treated with anti-
MRSA antibiotics [23]. This also holds true for the higher con-
sumption in Swiss ICU compared to non-ICU departments
observed in our study. These findings are consistent with those
of previous studies in Germany, which described higher glyco-
peptide consumption in ICU compared to non-ICU departments
and in university compared to non-university hospitals [24,25].
Our data reveal large variations in both MRSA incidence and
consumption of anti-MRSA antibiotics at the regional, hospital,
and even departmental levels (Supplementary Figure A1).
Seventy-three percent of the variance in consumption was
explained by different predictor variables, including MRSA inci-
dence and the interaction between MRSA incidence and
department. An analogous positive association between MRSA
incidence and consumption of glycopeptides was observed in
France during a single year in 2002, but the interaction between
MRSA incidence and department type was not analysed [26].
In our study, the effect of the number of MRSA infections on
the consumption of anti-MRSA antibiotics was more pronounced
in non-ICU departments than in ICU departments. This could be
explained by the early transfer of patients to the non-ICU
department for prolonged antibiotic therapy after initial stabi-
lization in the ICU. Further considering the critical condition of
ICU patients, it is likely that they more frequently receive anti-
MRSA antibiotics while awaiting microbiological results.
The VRE incidence in Switzerland is low. The absence of a
significant association between VRE incidence and the con-
sumption of anti-MRSA antibiotics should therefore be inter-
preted with care.
Since our data still showed considerable differences in the
consumption of anti-MRSA antibiotics within otherwise com-
parable hospitals, we developed an advanced model including
data on hospital policies. This model was restricted to data
from 2019, as hospital policy data were available for this year
only. In this model, 44% of the explained variability in con-
sumption was due to prescription restrictions and the estab-
lishment of regular meetings of an antibiotic stewardship
group. This positive effect is in line with the findings of Borde
et al., who reported a decline and optimization in the use of














































Figure 3. Association of antibiotic stewardship group (ABS), restrictions on the prescription of anti-MRSA antibiotics (Restrictions) or both
(ABS group & Restrictions) with the consumption of anti-MRSA antibiotics (defined daily doses (DDD) per 1000 bed-days) in 15 Swiss
university (turquoise) and non-university (grey) hospitals in 2019. Both individual data points and group medians (lines) are shown.
Consumption data were grouped per intensive care unit (ICU) (left panel) and non-ICU department (right panel).
L. Renggli et al. / Journal of Hospital Infection xxx (xxxx) xxx6programme [27]. In our study, we did not analyse the effects of
the optimized use of anti-MRSA antibiotics, but, as suggested
by other studies, these interventions may not only reduce
resistance rates but also decrease patient harm due to side-
effects, mortality, and costs [27,28].
In contrast to the whole study period, variability in con-
sumption of anti-MRSA antibiotics between hospitals was not
explained by MRSA incidence in 2019. This may be explained by
lower MRSA incidence and especially lower variance in MRSA
incidence but comparable variance in consumption of anti-
MRSA antibiotics compared to the whole study period. In
addition, in model 1 the difference to the previous year was
considered by the variable time (year) which could not be
considered in model 2. Further, the statistical power was
weaker in model 2, due to smaller dataset.
Our study has several limitations. First, the two models are
not directly comparable, as only data from 2019 could be
included in model 2. However, both models fit well (R2 ¼ 0.73
each), and we assume that continuous surveillance of hospital
policies could even improve our model. Second, data were
grouped by department level. The inclusion of patient-specific
data could essentially improve these models. With the intro-
duction of electronic prescriptions, such an analysis will be
possible in the future. Third, MRSA cases were not confirmed by
a central laboratory; however, all participating laboratories
use Clinical and Laboratory Standards Institute or European
Committee on Antimicrobial Susceptibility Testing guidelines
and are accredited by the Swiss government.
The main strength of our study is the extensive data col-
lection, covering 11 years and all university and tertiary hos-
pitals in Switzerland. In addition, Switzerland uniquely allows
stratification into different linguistic and socio-cultural regions
within a single country. To the best of our knowledge, this is
the first multi-centre study investigating hospital policy-
dependent predictors for the use of anti-MRSA antibiotics.Please cite this article as: Renggli L et al., Consumption of anti-metic
associated with antibiotic stewardship measures, Journal of Hospital InfeIn conclusion, we found that daptomycin, when introduced,
did not replace glycopeptides, since consumption of all anti-
MRSA antibiotics examined in this study increased in Switzer-
land. It can also be concluded that, in addition to MRSA inci-
dence, both regional factors and hospital type affect anti-MRSA
antibiotic consumption, as significantly higher values were
found in the French- and Italian-speaking regions than in the
German-speaking region and in university hospitals than in non-
university hospitals. Considering antibiotic stewardship policies,
the presence of an antibiotic-stewardship group and the
implementation of prescription restrictions were associated
with a lower consumption of anti-MRSA antibiotics. Therefore,
appointing an antibiotic stewardship group in addition to
implementing restrictions in prescription for anti-MRSA anti-
biotics should be recommended.
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Akutkrankenhäusern [Recent antibiotic use in German acute care
hospitals e from benchmarking to improved prescribing and
quality care]. Dtsch Med Wochenschr 2015;140:e237e46.
[26] Rogues AM, Dumartin C, Lashéras A, Venier AG, Fourrier A,
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